S&P Futures
4,052.25 -32.00 (-0.78%) Dow Futures
33,853.00 -193.00 (-0.57%) Nasdaq Futures
12,087.25 -135.00 (-1.10%) Russell 2000 Futures
1,903.50 -16.00 (-0.83%) Crude Oil
79.21 -0.47 (-0.59%) Gold
1,937.90 -7.70 (-0.40%)
Ventyx Biosciences, Inc. (VTYX)
After hours:
Chart Events
Performance Outlook
| Previous Close | 38.00 |
| Open | 38.24 |
| Bid | 0.00 x 1000 |
| Ask | 0.00 x 900 |
| Day's Range | 38.01 - 43.78 |
| 52 Week Range | 9.50 - 43.81 |
| Volume | |
| Avg. Volume | 644,521 |
| Market Cap | 2.348B |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.77 |
| Earnings Date | Nov 03, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 52.82 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for VTYX
Related Research
- Ventyx Biosciences, Inc.Daily – Vickers Top Buyers & Sellers for 12/27/2022The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.RatingFair ValueEconomic Moatlast monthArgus Research
- Zacks
Wall Street Analysts Think Ventyx Biosciences, Inc. (VTYX) Could Surge 38.99%: Read This Before Placing a Bet
The consensus price target hints at a 39% upside potential for Ventyx Biosciences, Inc. (VTYX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
- GlobeNewswire
Ventyx Biosciences Announces Pipeline Updates and Highlights Strategic Priorities at Investor R&D Day
Phase 2 clinical trials of VTX958 (TYK2 inhibitor) in plaque psoriasis, Crohn’s disease and psoriatic arthritis are ongoing with topline Phase 2 data in plaque psoriasis expected in Q4 2023 The Phase 2 trial of VTX002 (S1P1R modulator) in ulcerative colitis is on track to complete enrollment by mid-2023; new pharmacodynamic data support best-in-class potential Releases new data highlighting attractive profiles of NLRP3 inhibitors VTX2735 and VTX3232 Discloses new small molecule discovery program
- Zacks
Here's Why Momentum in Ventyx Biosciences, Inc. (VTYX) Should Keep going
Ventyx Biosciences, Inc. (VTYX) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
